Abstract Prolactin (PRL) promotes the proliferation and survival of breast cancer cells in part via the transactivation of human epidermal growth factor receptor 2 (HER2), also known as Neu in rodents. A PRL receptor (PRLR) antagonist, G129R, has been developed, which indirectly inhibits the tyrosine phosphorylation of HER2 (p-HER2) in human breast cancer cell lines. In this study, we investigate the effects of cancer-associated fibroblasts (CAFs) upon this molecular cross-talk using tumor cells and CAFs derived from spontaneous mammary tumors of female MMTV-neu transgenic mice. Tumors were resected and cultured as small tumor chunks (*3 mm 3 ) or were cultured in monolayer. G129R reduced tyrosine phosphorylation of Neu (p-Neu) in a dose-dependent manner (IC 50 *10 lg/ml) in tumor chunks, but had no effect on primary tumor epithelial cells grown in monolayer. Direct co-culture of mouse or human tumor epithelial cell lines with CAFs restored the epithelial cells' response to G129R, similar to that observed in mouse tumor chunks. The addition of PRL, as expected, induced p-Neu in both the tumor chunk and co-culture models. The inhibitory effect of G129R was absent when CAFs were physically separated from mouse tumor epithelial cells using a transwell system, or when CAFs were replaced with normal fibroblasts in direct co-culture with human or mouse tumor epithelial cells. In vivo, G129R reduced p-Neu levels in primary mammary tumors of mice in a time-and dosedependent manner. In conclusion, CAFs play a critical role in bridging the cross-talk between PRL and HER2/Neu in both mouse and human models of breast cancer. The inhibitory effects of G129R on p-Neu and on tumor growth are dependent upon interactions of tumor epithelial cells with CAFs.
Introduction
Prolactin (PRL) is a hormone that can prevent apoptosis [1] , enhance tumor cell proliferation [2] [3] [4] , promote angiogenesis [5] , and increase cell motility and metastasis [3, 6] . PRL mediates its effects via the PRL receptor (PRLR) [7] and stimulates signaling via the Jak2-STAT5 [8] [9] [10] , Ras-Raf-MAPK [11] [12] [13] , and PI3K-Akt pathways. Studies have shown that PRLR is expressed in a majority of human breast cancers and is elevated in comparison with normal breast tissue [14] [15] [16] and that PRL levels are associated with increased breast cancer risk [17] [18] [19] .
Human epidermal growth factor receptor 2 (HER2) and the rat homologue, Neu, belong to the ErbB family of four transmembrane receptors involved in cell growth, differentiation, and survival [20] . HER2/Neu acts as a heterodimerization partner for other ErbB receptors, signaling through the PI3K-Akt, Ras-Raf-MAPK, and cAMP-PKA signaling pathways [20] . Studies have shown that overexpression of HER2 has significant correlations with aggressive tumor behavior and poor prognosis [21] .
In breast cancer, cross-talk between PRLR and steroids/ growth factors, such as estrogen [22] , progesterone [23] , EGF/TGF-a [24] , and IGF-1 [25] , are well characterized. In contrast, cross-talk between PRLR and HER2 is poorly understood. Previously, we have reported that PRL induces p-HER2 and enhances MAPK activity in T-47D and BT-474 human breast cancer cells and that this signaling can be inhibited by trastuzumab [26] . The interaction between these two receptors may be of significance in the progression of carcinogenesis. Therefore, targeting both HER2 and PRLR is considered as a potential therapeutic strategy for HER2-positive breast cancer.
Several types of stromal cells, such as cancer-associated fibroblasts (CAFs), endothelial cells, inflammatory cells, and extracellular matrix (ECM), collectively create the microenvironment for epithelial cells [27] . Many transmembrane components, ECM proteins, and growth factors secreted by CAFs have been demonstrated to induce cell proliferation [27] . The tumor microenvironment is a crucial factor in determining tumor response to therapeutic drugs. Tumor cells may interact with soluble factors secreted by stromal cells or directly with surface molecules, and ECM secreted by stromal cells [28] . Therefore, contrary to the classical model of monoculturing tumor epithelial cells, it is important to rebuild the tumor system with components of their microenvironment, such as CAFs, to accurately evaluate and predict drug response and other tumor behaviors. Previously, we have reported that a PRLR antagonist, G129R, may represent a new therapeutic agent for HER2-positive breast cancer [26] . In this study, we report that CAFs play an important role in bridging the cross-talk between PRLR and HER2/Neu signaling in both the mouse and human models of breast cancer.
Materials and methods

Transgenic mice
Breeding pairs of FVB/N-Tg(MMTVneu)202Mul/J mice, expressing the wild-type rat neu transgene under the control of the mouse mammary tumor promoter (MMTV-neu), were obtained from The Jackson Laboratory (Bar Harbor, ME). The colony was expanded and housed in accordance with The Guide for the Care and Use of Laboratory Animals. All animal studies were reviewed and approved by Clemson University Institutional Animal Care and Use Committee.
Cell lines and reagents
MCNeuA epithelial and N202Fb3 CAF clonal cell lines established from a female MMTV-neu mouse mammary tumor were gifted by Dr. Michael Campbell (University of California, San Francisco, CA) [29] . Human SK-BR-3 breast cancer cells and CRL-7236 primary human CAFs were obtained from the ATCC (Manassas, VA). Two types of primary mouse embryonic fibroblasts (MEFs) were derived from the embryos of non-transgenic (NTG-MEFs) and MMTV-neu transgenic (NEU-MEFs) FVB/N mice as described previously [30] . All cell lines were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 10 lg/ml gentamicin at 37°C in a 5% CO 2 humidified atmosphere. All cell culture reagents were purchased from Invitrogen (Carlsbad, CA). The recombinant human PRL and its antagonist analog, G129R, used for all experiments were prepared in-house as described previously [26] .
Preparation of tumor chunks and primary tumor cells
Spontaneous mammary tumors from female MMTV-neu mice were resected, rinsed in ice-cold phosphate buffered saline (PBS), and minced into tumor chucks (*3 mm 3 ) using a sterile scalpel. A portion of the tumor chunks were minced further, incubated in 0.25% trypsin-EDTA (Invitrogen) for 30 min at 37°C with constant mixing, and filtered through a 100-lm cell strainer. The cell suspension was centrifuged at 800 9g for 10 min and resuspended and incubated in ACK lysing buffer (Lonza, Walkersville, MD) for 10 min before filtration through a 40-lm strainer. The single cell suspension of primary tumor cells were centrifuged at 300 9g for 10 min, resuspended in PBS, and the cells were counted with a hemocytometer.
FACs analysis of primary tumor cells
Primary tumor cells (3 9 10 5 cells) were suspended in 30 ll of rat anti-EpCAM (14-5791-81; eBioscience, San Diego, CA) diluted in PBS (1:1,000), incubated for 15 min on ice, and centrifuged at 500 9g for 2 min. This process was repeated using goat anti-rat IgG-PE (sc-3740; Santa Cruz Biotechnology, Santa Cruz, CA) diluted in PBS (1:60), rabbit anti-PRLR (M170) (sc-30225; Santa Cruz Biotechnology) diluted in PBS (1:30), and goat anti-rabbit IgG-FITC (sc-2012; Santa Cruz Biotechnology) diluted in PBS (1:60). Finally, the cells were suspended in 400 ll of PBS, and the surface expressions of EpCAM and PRLR were evaluated by flow cytometry with a FACScalibur instrument using CellQuest software (Becton-Dickinson, San Jose, CA). As negative controls, irrelevant antibodies of the same isotypes (Becton-Dickinson) were used in replacement of anti-EpCAM and anti-PRLR. The fluorescences of PE and FITC were excited with an argon laser at 488 nm and detected at 570 and 530 nm, respectively.
Immunohistochemical and H&E staining
Tumor chunks were fixed with 10% neutral buffered formalin overnight, paraffin embedded, and sections (5 lm)
were mounted on slides. Deparaffinized tissue slides were rehydrated, and heat-induced epitope retrieval was performed in citrate buffer using a pressure cooker (20 min at 80 pKA). MCNeuA and N202Fb3 cells were mono-or cocultured at a ratio of 4:1 on poly-prep slides (SigmaAldrich, St. Louis, MO) in DMEM supplemented with 10% FBS for 24 h at 37°C in a 5% CO 2 humidified atmosphere. Cells were fixed with 10% neutral buffered formalin for 10 min and permeabilized in 10% Triton X-100 for 10 min. For immunohistochemical staining, endogenous peroxidase activity was blocked with 3% H 2 O 2 in PBS for 10 min before blocking in horse serum for 30 min. Slides were incubated overnight in horse serum with a 1:2,000 dilution of rabbit anti-cleaved caspase-3 (9961; Cell Signaling, Beverly, MA), a 1:500 dilution of rabbit anti-Ki-67 (ab16667; Abcam, Cambridge, MA), a 1:1,000 dilution of mouse anti-vimentin (ab7752; Abcam), a 1:200 dilution of rabbit anti-E-cadherin (4065; Cell Signaling), or as a negative control a 1:200 dilution of mouse or rabbit IgG. The UltraVision ONE Detection System HRP Polymer and DAB Plus Chromogen kit (Thermo Scientific, Rockford, IL) was used to detect all antigens. The slides were counterstained with hematoxylin and bluing reagent and mounted with coverslips using Permount mounting medium (Fisher Scientific). For H&E staining, deparaffinized slides were stained with hematoxylin for 5 min, washed with acid alcohol for 30 s, and then stained with eosin for 2 min (all from Sigma). Slides were imaged with an Olympus microscope, and images were obtained with a CCD-cooled 1.5-megapixel camera.
In vitro culture and treatment of tumor chunks and primary tumor cells After washing in PBS, the tumor chunks were immediately seeded into six-well tissue culture plates. The PBS was aspirated and replaced with 2 ml of serum-free DMEM containing PRL or G129R treatments, and the tumor chunks were cultured for 24 h at 37°C in a 5% CO 2 humidified atmosphere. After cell counting, the tumor cell suspensions were immediately centrifuged, suspended in DMEM supplemented with 10% FBS, and seeded (1 9 10 6 cells/well, in 2 ml) into six-well tissue culture plates. The cells were monolayer cultured for 24 h at 37°C in a 5% CO 2 humidified atmosphere before treatment with PRL or G129R for 24 h. The tumor chunks and primary tumor cells were rinsed with ice-cold PBS and cell lysate was prepared as described below.
Epithelial cell-fibroblast direct co-culture All cells were trypsinized, resuspended in DMEM supplemented with 10% FBS, and counted with a hemocytometer. MCNeuA cells were mixed with various ratios of N202Fb3 CAFs (1:4, 1:2, 1:1, 2:1, 4:1, or 8:1) or with a 4:1 ratio of NTG-MEFs or NEU-MEFs; SK-BR-3 cells were mixed at a 4:1 ratio with N202Fb3 CAFs, NTGMEFs, NEU-MEFs, or human CAFs. The cells were seeded (1 9 10 6 cells/well, in 2 ml) in six-well tissue culture plates and incubated for 24 h at 37°C in a 5% CO 2 humidified atmosphere. The cells were serum-starved in DMEM supplemented with 0.5% charcoal/dextran-treated FBS (SH30068.03; Thermo Scientific) for 1 h before treatment with PRL (0, 0.1, 0.2, 0.5, 1.0, or 2.0 lg/ml) or G129R (0 or 10 lg/ml) for 24 h. The cells were rinsed with ice-cold PBS and cell lysate was prepared as described below.
Epithelial cell-fibroblast transwell co-culture All cells were trypsinized, resuspended in DMEM supplemented with 10% FBS, and counted with a hemocytometer. MCNeuA epithelial cells were seeded in six-well tissue culture plates (8 9 10
5 cells/well, in 2.6 ml) and N202Fb3 CAFs, NTG-MEFs, or NEU-MEFs (2 9 10 5 cells/insert, in 1.5 ml) were seeded above the MCNeuA cells on 24 mm Transwell with 0.4 lm pore polycarbonate membrane inserts (3412; Corning, Corning, NY) and incubated for 24 h at 37°C in a 5% CO 2 humidified atmosphere. The cells were serum-starved in DMEM supplemented with 0.5% charcoal/ dextran-treated FBS for 1 h before treatment with G129R or PRL for 24 h. The inserts were discarded and the MCNeuA cells were rinsed with ice-cold PBS and cell lysate was prepared as described below.
Epithelial cell-fibroblast cell debris co-culture N202Fb3 CAFs were seeded in 100 cm 2 dishes and grown to confluence. Cells were harvested by scraping in PBS and the cells were disrupted by freeze/thaw and homogenized in a Potter-Elvehjem homogenizer. Insoluble material was harvested by centrifugation at 1,000 9g for 5 min at 4°C and suspended in DMEM supplemented with 10% FBS. Insoluble components containing crude cell membrane were mixed with MCNeuA cells at various ratios and seeded (1 9 10 6 cells/well, in 2 ml) into six-well cell culture plates. The cells were serum-starved in DMEM supplemented with 0.5% charcoal/dextran-treated FBS for 1 h before treatment with G129R or PRL for 24 h. The cells were rinsed with ice-cold PBS and cell lysate was prepared as described below.
Preparation of tissue and cell lysate
Whole lysate was prepared in RIPA buffer (50 mM TrisÁHCl, pH 7.4; 150 mM NaCl; 1% NP40; 0.25% Na- deoxycholate; 1 mM EDTA, pH 8.0) supplemented with 19 protease and 19 phosphatase inhibitors (78430 and 78428; Thermo Scientific). Tumor chunks were transferred to tubes, weighed, and suspended in lysis buffer at a concentration of 250 mg/ml, and homogenized with a Polytron homogenizer. Cells cultured as monolayers in six-well plates were lysed in 0.2 ml of lysis buffer. Clarified lysate and protein content were prepared as described previously [26] .
Immunoprecipitation of PRLR
Cells were grown to confluence in 100 cm 2 dishes, rinsed with ice-cold PBS, and lysed as described above. Approximately 1 mg of clarified cell lysate was incubated overnight with 5 lg of rabbit anti-PRLR (M170) (sc-30225; Santa Cruz Biotechnology) and 25 ll of protein G-Sepharose slurry (GE Healthcare Sciences). The immunoprecipitate was washed in lysis buffer and suspended in sample buffer. Whole cell lysate and immunoprecipitate were resolved by SDS-PAGE and western blotted for PRLR as described below.
SDS-PAGE and western blot analysis
Lysate from tissue or cells (30-60 lg) was mixed with an appropriate volume of 69 sample buffer and heated at 98°C in a heating block for 2 min. Lysate was resolved on 4-15% gradient polyacrylamide gels (Bio-Rad, Hercules, CA) and transferred to nitrocellulose membranes as described previously [26] . The membranes were incubated overnight in blocking buffer (5% non-fat milk in TBST) with a 1:1,000 dilution of rabbit anti-phospho-Neu (Tyr 1,248) (sc-12352; Santa Cruz Biotechnology), a 1:1,000 dilution of rabbit anti-Neu (sc-284; Santa Cruz Biotechnology), a 1:1,000 dilution of rabbit anti-PRLR(H300) (sc-20992; Santa Cruz Biotechnology), a 1:10,000 dilution of mouse anti-b-actin (A1978; Sigma-Aldrich), or a 1:1,000 dilution of mouse anti-b-tubulin (sc-55529; Santa Cruz Biotechnology). Detection was carried out using either a 1:2,000 dilution of horse radish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (Bio-Rad), and ECL detection reagent (GE Healthcare Sciences, Piscataway, NJ). Blots were imaged and analyzed by the FluorChem Q Imaging System and AlphaView Q software (Cell Biosciences, Santa Clara, CA).
Biopsy and treatment of spontaneous mammary tumors in female MMTV-neu mice
Tumor-bearing MMTV-neu female mice were anesthetized. A small incision was made next to the tumor, and a piece (*0.05-0.2 g) of tumor was excised and frozen on dry ice. The incision was closed with 9-mm auto clips (Clay Adams-Becton-Dickinson and Company, Sparks, MD), and the mice were allowed to recover from surgery for 48 h. The mice were injected intraperitoneally with Vehicle or G129R for various intervals of time. Approximately 24 h after the final injection, mice were euthanized, and tumors were resected and frozen on dry ice. Pre-and post-treatment biopsies were lysed and blotted as described above.
Results
Characterization of tumor chunks and primary tumor cells
Tumors were resected from female MMTV-neu mice and processed into chunks (Fig. 1a , left pane) and cell suspensions. A portion of the tumor chunks were immunohistochemically stained for Ki-67 and cleaved caspase 3 to examine their proliferative and apoptotic activity or were histochemically stained with H&E to examine their overall epithelial content. Epithelial cells in the tumor chunks were clearly surrounded by mesenchymal cells (Fig. 1a , middle pane) and consistently exhibited a high degree of mitotic activity and a low degree of apoptotic activity (Fig. 1b) . Primary tumor cell suspensions were prepared from a portion of the tumor chunks. To examine the epithelial purity of the cell suspensions and whether or not the cells should respond to G129R, the surface expression of epithelial cell adhesion molecule (EpCAM) and PRLR were evaluated by flow cytometry. After processing, the primary tumor cells isolated from the tumor chunks were found to be almost entirely epithelial by flow cytometry ([99% EpCAM-positive cells; mean fluorescence intensity [1,700) (Fig. 1c, left pane) , which was visually confirmed upon examination of the cells 24 h after seeding on tissue culture plates (Fig. 1a, right pane) . A majority of the Ep-CAM-positive primary tumor cells were confirmed to express PRLR (Fig. 1c, middle and right pane) .
Inhibition of p-Neu by G129R is dependent upon tumor microenvironment
In this study, we examined the effects of PRL and G129R upon p-Neu (Tyr 1,252) in the MMTV-neu mouse model of HER2-positive breast cancer, homologous to p-HER2 (Tyr 1,248). Other studies have shown that p-HER2 is enhanced by PRL [31] and inhibited by G129R [26] in human breast cancer epithelial cells. In contrast to these studies, G129R had little or no effect upon p-Neu in the primary epithelial cells isolated from MMTV-neu tumors when cultured in monolayer (Fig. 2a) ; however, G129R inhibited p-Neu (Fig. 2a) and PRL induced p-Neu (Fig. 2b) in a dosedependent manner, when the primary epithelial cells from the same tumors were maintained as tumor chunks. Initial experiments showed that similar alterations were observed in p-Neu (Tyr 1,225/1,226) and in p-Neu (Tyr 881) located in the kinase domain of Neu (data not shown).
Direct co-culture of tumor epithelial cells with CAFs restores epithelial cell response to G129R and PRL The discrepancy between the response to G129R or PRL in tumor chunks and the lack thereof in primary tumor epithelial cells may be due to the absence of tumor microenvironment components. The importance of CAFs in mediating the inhibitory effect of G129R upon p-Neu was examined by directly co-culturing MCNeuA epithelial cells with N202Fb3 CAFs established from a spontaneous MMTV-neu mammary tumor. MCNeuA cells were confirmed to express the epithelial marker E-cadherin and N202Fb3 CAFs were confirmed to express the mesenchymal marker vimentin (Fig. 3a, upper pane) . Similar to what was observed in vivo (Fig. 1a, middle pane) , the MCNeuA epithelial cells formed islets surrounded by small nest-like clusters of N202Fb3 CAFs (Fig. 3a, lower pane) . Western blot analysis confirmed that both cell lines express low levels of PRLR (Fig. 3b) , but that the expression of Neu was limited to MCNeuA epithelial cells and was absent in N202Fb3 CAFs (Fig. 4a) . Treatment with G129R (10 lg/ ml) had minimal effect, if any, on p-Neu when MCNeuA cells were cultured alone (Fig. 4a) ; similar to what was observed with primary epithelial cells (Fig. 2a) . In contrast, treatment with G129R reduced p-Neu when the MCNeuA cells were co-cultured with N202Fb3 CAFs at a 2:1 or 4:1 ratio, with the maximum reduction being observed at a 4:1 ratio (Fig. 4a) . Under similar conditions, PRL stimulated p-Neu in a dose-dependent manner in MCNeuA cells cocultured with N202Fb3 CAFs (Fig. 4c) . Time-course experiments revealed that the co-cultured cells had to be 
treated with G129R for at least 24 h to observe a significant reduction in p-Neu (Fig. 4b) .
CAFs have properties absent in normal fibroblasts that modulate the effects of G129R and PRL upon p-Neu
Using the same direct co-culture system, we evaluated whether or not CAFs could be replaced with normal NTGMEFs or NEU-MEFs. The MEFs grew less robustly than CAFs but still formed nest-like structures around the MCNeuA cell islets (data not shown). Treatment with G129R (10 lg/ml) for 24 h reduced p-Neu in MCNeuA cells co-cultured with N202Fb3 CAFs, but not in MCNeuA cells co-cultured with either of the MEFs (Fig. 5a ).
Inhibition of p-Neu by G129R is dependent upon tumor epithelial-stromal interactions and not secreted soluble factors
Since the modulation of p-Neu required CAFs and took at least 24 h to occur, it is likely that PRL and G129R are modulating the synthesis of bioactive molecules (ECM and/or growth factors) in CAFs which are not aberrantly expressed in MEFs. To determine if the influence of CAFs on G129R response was mediated by direct cell-cell and/or cell-matrix contacts, or via the secretion of soluble factors, MCNeuA cells and N202Fb3 CAFs were co-cultured together or in close proximity separated by a permeable membrane. Using the transwell system, MCNeuA cells were placed in the bottom chamber, and N202Fb3 CAFs were placed on the transwell insert; treatment with G129R (10 lg/ml) for 24 h had no effect upon p-Neu in the absence of cell-cell and/or cell-matrix contact (Fig. 5c) . To exclude the simple requirement for direct cell-cell interactions between MCNeuA cells and N202Fb3 CAFs, the crude membrane extracts of N202Fb3 CAFs were incubated with MCNeuA cells at a 2:1, 4:1, and 8:1 ratio (MCNeuA:N202Fb3). Treatment with G129R (10 lg/ml) for 24 h had no effect upon p-Neu (Fig. 5b) , suggesting that the effects of PRL and G129R upon p-Neu are dependent upon ECM components secreted by CAFs.
G129R reduces p-Neu level in vivo
To assess the efficacy of G129R in vivo, a self-comparison model was developed using pre-and post-treatment tumor biopsy samples to compare the levels of p-Neu before and after treatment with G129R. Spontaneous tumors arising in female MMTV-neu mice were allowed to reach *1 cm in diameter before tumor biopsy. Two days after biopsy, mice were treated with various doses of G129R for five or ten days. Approximately 24 h after the final treatment, the tumors were removed. G129R treatment reduced p-Neu, with a noticeable reduction being seen with 5 mg/kg/day dose and maximal reduction being seen with 10 mg/kg/day dose (Fig. 6a) . The inhibitory effect of G129R upon p-Neu was observed in as few as 5 days and was sustained after 10 days of treatment (Fig. 6b) .
Having optimized the dose of G129R (10 mg/kg/day), we tested the response to G129R or vehicle on a greater number of mice. All of the mice receiving 5-day or 10-day treatment with vehicle retained substantial levels of p-Neu (Fig. 6c) . Fourteen mice with spontaneous tumors received a 5-day treatment of G129R (10 mg/kg/day, i.p.) with the goal to reduce p-Neu. Five mice were highly responsive, four were moderately responsive, and five were unresponsive, with a total response rate of 64% (9/14). Ten mice received a 10-day treatment of G129R (10 mg/kg/day, i.p.) with the goal to reduce p-Neu. Tumors from three mice were highly responsive, five were moderately responsive, and two were unresponsive, with a total response rate of 80% (8/10). A subset of the results for the 5-day (Fig. 6b ) and 10-day (Fig. 6c) 
Modulation of p-HER2 in human breast cancer cells by G129R is dependent upon CAFs
To expand the validity of this direct co-culture model, SK-BR-3 human breast cancer cells which overexpress HER2 and PRLR were used. Treatment with G129R for 24 h had a minimal effect, if any, on p-HER2 when SK-BR-3 cells were grown alone in monolayer (Fig. 7a) . When SK-BR-3 cells were co-cultured at a 4:1 ratio with human CAFs, a reduction in p-HER2 was observed after 24 h treatment with G129R (10 lg/ml) (Fig. 7a) . A similar response was observed when SK-BR-3 cells were co-cultured with mouse N202Fb3 CAFs, but not normal MEFs, indicating that CAFs derived from mice or humans possess the ability to mediate cross-talk between PRLR and Neu in human tumor cells (Fig. 7b) .
Discussion
HER2-overexpressing breast cancers are marked with a poor prognosis and fewer successful therapeutic options [21, 32] . Trastuzumab is a targeted therapy for the management of HER2-positive metastatic breast cancers; unfortunately, the majority of patients that initially respond to treatment develop resistance resulting in disease progression [33] . The relative refractory state of these HER2-positive breast carcinomas illustrates the need to examine The figure shows results from one of three experiments from which the same overall conclusion could be drawn. Paired t test was used. *means P value is \0.05, and **Means P value is \0.01 the mechanisms underlying tumor drug resistance and the necessity to examine novel combinations with other agents.
Difficulty in treating HER2 breast cancers may be associated with alterations within the tumor microenvironment, which afford a survival advantage following drug exposure and may facilitate the acquisition of drug resistance [34] . Interactions with soluble factors, such as stroma-secreted interleukins, are capable of enhancing tumor cell survival and countering apoptosis [28] . Direct interactions with ECM components in the tumor microenvironment may activate cell adhesion molecules, such as the integrins, and result in the activation of signal transduction pathways that block drug-induced apoptosis [35] . Both of these tumor cell-environment interactions may be mediated by CAFs which often express increased amounts of peptide growth factors, cytokines, and ECM components [36] . CAFs are a crucial component of the tumor microenvironment and are receiving increased attention because of their participation in tumor development, including invasion and metastasis, and their ability to act as markers of patient prognosis [37] . Human breast carcinomas overexpressing HER2 have been shown to have higher proliferative and metastatic activity in the presence of autocrine PRL [31] . PRL was shown to stimulate p-HER2 and enhance MAPK activity in human breast cancer cell lines co-expressing HER2 and PRLR [26, 31] and treatment with a PRLR antagonist, G129R, suppressed p-HER2 and had an additive growth inhibitory effect when combined with trastuzumab in human breast cancer xenografts [26] . In this study, we used MMTV-neu mice bearing spontaneous tumors as a model of HER2 breast cancer to further examine the efficacy of G129R in vivo. Compared to pretreatment tumor biopsies, G129R decreased p-Neu in a dose- (Fig. 6a) and timedependent (Fig. 6b) manner after 5 days of treatment and p-Neu was nearly abolished after 10 days of treatment (Fig. 6b ) in a majority of the mice. Likewise, p-Neu was reduced in the group of mice randomized to receive G129R (10 mg/kg/day) compared with the group that received the Vehicle (Fig. 6c) . Similar to the in vivo studies, but to a lesser extent, G129R (10 lg/ml) was able to reduce p-Neu in cultured tumor chunks (Fig. 2a, b) ; however, it had no effect on monocultures of primary epithelial cells (Fig. 2a) or an epithelial cell line (MCNeuA) derived from a spontaneous mammary tumor of an MMTV-neu mouse (Fig. 4a) . These results suggest that cross-talk between the PRLR and Neu is only observed when the tumor microenvironment is intact.
We demonstrate that the response to G129R and PRL can be restored when MCNeuA cells are co-cultured with N202Fb3 CAFs (Fig. 4a-c) and that replacement of CAFs with normal NTG-MEFs or NEU-MEFs failed to reduce p-Neu in response to G129R (Fig. 5a ). Considering that MCNeuA cells and N202Fb3 CAFs are derived from the same mammary tumor of a female MMTV-neu transgenic mouse, it is clear that adding back CAFs, at least partially, Similar results were observed using human cells, G129R had no effect upon p-HER2 in SK-BR-3 cells when grown in monoculture or co-culture with normal NTG-MEFs or NEU-MEFs (Fig. 7b) . Cross-talk between the PRLR and HER2 was only observed when SK-BR-3 cells were cocultured with human CRL-7,236 CAFs (Fig. 7a) or mouse N202Fb3 CAFs (Fig. 7b ). This suggests that CAFs are the mediator of cross-talk between PRLR and HER2/Neu and that CAFs share some features that enable them to act across species. We believe the mechanism of cross-talk between the PRLR and HER2 is different from the one reported previously in human breast cancer cell lines. Fast and sustained stimulation of p-HER2 and p-MAPK has been reported to occur in response to PRL in human breast cancer cell lines in the absence of CAFs, which is dependent upon the kinase activity of JAK2 to recruit the association of Grb2 with HER2; likewise, a reduction in p-HER2 and p-MAPK has been reported to occur in response to anti-PRL and G129R in human breast cancer cell lines in the absence of CAFs [26, 31] . In our experiment, the modulation of p-Neu in MCNeuA cells (Figs. 4a,  5a ) and p-HER2 in SK-BR-3 cells (Fig. 6a, b) required the presence of CAFs and was not observed in their absence. It should be noted that the means by which p-HER2 was analyzed in SK-BR-3 cells differed between our study and that of Yamauchi et al. [31] . They analyzed p-HER2 by immunoprecipitating HER2 and western blotting for total tyrosine phosphorylation; whereas, we blotted for the phosphorylation of the C-terminal tyrosine residue of HER2/Neu that has been reported to serve as docking site for adapter proteins that modulate MAPK activity and to be necessary for Neu-induced transformation and HER2-induced cell migration [38, 39] . Also, in contrast to this rapid modulation of p-HER2 by PRL in human breast cancer cells, the cross-talk we observed was delayed. Inhibition of p-Neu in response to G129R in co-cultured MCNeuA cells (Fig. 4b) and inhibition of p-HER2 in cocultured SK-BR-3 cells (Fig. 7a) was not significant until approximately 24 h after treatment. Similarly, inhibition of p-Neu in tumors of MMTV-neu mice appeared to be less after 5 days treatment than after 10 days treatment with G129R (Fig. 6b) . Since the cross-talk we observed between the PRLR and HER2/Neu required CAFs and took longer to observe, it would appear to be via a different mechanism than the one previously reported to occur in monocultures of human breast cancer cell lines. We speculate that G129R is inhibiting, and PRL is stimulating, the synthesis of a bioactive molecule by CAFs that modulates p-HER2/Neu.
A transwell system was used to physically separate MCNeuA cells from N202Fb3 CAFs, yet still allow soluble secreted molecules to permeate back and forth between the cells. G129R had no effect on p-Neu in the absence of cellcell and/or cell-matrix contacts (Fig. 5c) , suggesting that the bioactive molecule is not a soluble growth factor. MCNeuA cells cultured with membrane components of N202Fb3 CAFs did not restore cross-talk either (Fig. 5b) , suggesting that the bioactive molecule is not a component of the CAF plasma membrane. Through the process of elimination, we speculate that PRL and G129R modulate the expression of an ECM component by CAFs and that this ECM component enables cross-talk between the PRLR and Neu to occur in epithelial cells. It should be noted that considerable variability was observed in the reduction of p-Neu in response to G129R (*20-50%) even though the ratio of MCNeuA cells to N202Fb3 cells (4:1) and course of incubation with G129R (10 lg/ml) were identical among many of the co-culture experiments (Figs. 4b, 5a vs. 4a, 5a) . Some of this variability may be attributed to fluctuations in the proliferation rates among the MCNeuA cells and N202Fb3 CAFs, which resulted in morphological changes in the size and shape the nest-like structures formed between the cells (Fig. 3a , lower pane), and reflects an alteration in the interactions between the epithelial cells and CAFs. Since G129R reduced p-Neu significantly at a 4:1 ratio but not at a 8:1 ratio (Fig. 4a) , larger nest-like structures formed because of excessive MCNeuA cell proliferation may have reduced the critical interactions with CAFs. A net reduction in p-HER2 was observed when SK-BR-3 cells were incubated with MEFs because of alterations in proliferation (Fig. 7b) . SK-BR-3 cells proliferated more slowly in the presence of MEFs than CAFs resulting in large nests of fibroblasts surrounding small islets of SK-BR-3 cells. The largest variable appears to be due to differences in cell passage numbers, particularly in the CAFs. Many of our late passage N202Fb3 cells lost the ability to modulate p-Neu in MCNeuA cells. We speculate that these variables alter the synthesis and deposition of an ECM component by the CAFs, necessary for cross-talk between the PRLR and Neu.
As integrins are the receptors that mediate attachment between cells and ECM, we believe that integrins may play a critical part in the cross-talk between epithelial cells and fibroblasts. The possible association between PRLR and HER2/Neu may be induced by integrins when the two cell types establish physical contact via ECM. Studies have shown that the integrin-mediated adhesion to ECM components modulates the responsiveness of epithelial cells to PRL. Interaction of b1-integrin with the basement membrane component laminin 1 modulates the ability of PRL to stimulate STAT5 DNA-binding activity and express milk proteins, while the interaction of the same integrin with the stromal component collagen I does not [40] [41] [42] . Interactions between the PRLR/b1-integrin complex and collagen I has recently been shown to modulate the responsiveness of breast cancer cells to PRL and to contribute to breast cancer progression [43] . In another study, the cell surface molecule b4-integrin was shown to form a complex with Neu in mouse mammary tumors [44] . We speculate that the cell and environmental interactions mediated by integrins in tumors may play an important role in inducing cross-talk between PRLR and HER2/Neu on tumor cells and influence their responsiveness to therapeutic agents such as G129R.
In summary, we demonstrate that CAFs, but not normal fibroblasts, play an important role in mediating cross-talk between PRL and HER2/Neu and that the inhibitory effect of G129R on p-HER2/Neu in tumor epithelial cells is likely dependent on interactions with insoluble ECM components secreted by CAFs. Furthermore, G129R is able to effectively decrease p-Neu in spontaneous MMTV-neu mouse mammary tumors. Our result suggests that monoculture models may have poor pre-clinical predictive value for drug response. Caution must be taken when extrapolating the clinical benefits of drugs using monocultured breast cancer cell lines because of fundamental differences in cell behaviors between monoculture and co-culture systems in the context of tumor microenvironment. The direct coculture model and in vivo studies highlight the significant difference in response to PRL and G129R when compared to monoculture systems, further proving the importance of an accurate model for therapeutic drug evaluation in the preclinical settings.
